Two Zebron GC products win R+D 100 awards
Phenomenex
Zebron ZB-Bioethanol column
R+D Magazine has given R+D 100 awards to two of Phenomenex's gas chromatography products - the Zebron ZB-Bioethanol column for biofuel testing and the Zebron ZB-Drug-1 column for analysing narcotics.
The awards, determined by an independent judging panel and the editors of R+D Magazine, recognise the 100 most technologically significant products introduced during the past year.
The Zebron ZB-Bioethanol column meets the biofuel industry's need for fast certification and shipment of product.
It resolves a number of challenges facing bioethanol plants, providing accurate analysis of fuel samples in one-eighth of the time of other columns.
The second winner is the Zebron ZB-Drug-1 column, which quickly and accurately tests for drugs of abuse such as opiates, marijuana and cocaine, in forensic applications and job-applicant screening.
Zebron ZB-Drug-1 successfully eliminates problems associated with analysing biological samples by providing a unique selectivity that resolves target analytes from matrix interferences.
Zebron's proprietary technology provides lower bleed levels than other columns, giving lower detection limits.
More stories
Online selection tool from Phenomenex
Guard Finder is a new interactive online tool for selection of column protection products
Protection system extends UHPLC column life
Phenomenex has launched Securityguard Ultra, a protection system that extends UHPLC column life and is said to be suitable for virtually any manufacturer's UHPLC, sub-2-micron or core-shell columns.
Column phase helps resolve aromatic hydrocarbons
Phenomenex has launched a Phenyl-Hexyl phase that is claimed to offer a 'unique selectivity' for the separation of compounds that are difficult to resolve using traditional phenyl phases.
SPE sorbent for drugs-of-abuse extraction
Phenomenex has introduced Strata-X-Drug N, its second solid-phase extraction (SPE) sorbent designed for the extraction of drugs of abuse in forensic toxicology.
Case study demonstrates results of API analysis
Phenomenex has announced the publication of a case study, written by scientists at Pfizer, that demonstrates the results of a new method for residual API (active pharmaceutical ingredient) analysis.
